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The condition characterized by elevated gonadotrophins (gonadotropins elevated into the menopausal range), low sex steroids,
and menstrual disorders was previously termed Premature Ovarian Failure (POF). However, over the last two years an eﬀort has
been made by many authors to have the term Primary Ovarian Insuﬃciency (POI) exclusively applied. Irrespective of the term, the
condition concerns adolescent and young adult women under 40 years who experience cessation of menstruation for more than 3
cycles (whereas these women in the past had a rhythmic menstrual cycle) or amenorrhea for 4–6 months against the background
of a previously disturbed menstrual cycle. Determining the cause of POI is diﬃcult, and it is even harder to deal with problems
arising from the paucity of estrogen as well as to draw up the plan for long-term monitoring of these patients. This paper presents
long-term therapeutic management strategies concerning emotional health, hormone replacement therapy, maintenance of bone
health, family planning, other associated disorders as well as possible research options for the future.
1.Introduction
Several diﬀerent terms have been used to describe what
Fuller Albright in 1942 originally named “Primary Ovarian
Insuﬃciency” (POI) [1, 2] .As e a r c hb yC o o p e re ta l .o f
PubMed [3]revealedthatthefollowingtermshavebeenused
to describe POI: gonadal dysgenesis, premature ovarian fail-
ure (POF), premature menopause, early menopause, hyper-
gonadotropic hypogonadism, ovarian dysgenesis, primary
ovarian failure, hypergonadotropic amenorrhea, primary
ovarian insuﬃciency, climacterium praecox, or menopause
praecox.
Investigation into POI is very complex, and in the
overwhelming majority of cases (90%) a clear-cut cause is
not found [4]. The most common causes are presented in
Table 1, while rare cases where POI is the single manifesta-
tion of an multiorgan syndrome have also been reported [5].
POI occurs through two major mechanisms either follicle
dysfunction or follicle depletion.
Diagnosis of POI is conﬁrmed when in the investigation
of menstrual disorders the following are observed: FSH
levelsgreaterthan30–40mIU/mL(varyingbetweendiﬀerent
laboratories), in two measurements in a one-month period,
and estradiol levels less than 50pg/mL (which indicate
hypoestrogenism). The most commonly observed menstrual
disorderissecondaryamenorrhea,whileforyoungerpatients
primary amenorrhea is also observed [6]. Bleeding patterns
may also include oligomenorrhea, polymenorrhea, or dys-
functional uterine bleeding usually prior to ﬁnal cessation
of menstruation. In the case of teenagers, deﬁnitive early
diagnosis is diﬃcult because these concomitant disorders
are very frequent in puberty and less than 10% of these
adolescents suﬀer ultimately from POI [7]. The reason we
need to expedite diagnosis is the rapidity of establishment
of osteopenia (up to 60% of adolescents at the time of
diagnosis) or, rarely, osteoporosis caused by it [8].
As mentioned earlier, POI results from either rapid
atresia of primordial oocytes or the impairment of existing
follicles. Ultrasonographic identiﬁcation of follicles >3mm,
the advent of menstruation, and the measurement of plasma
oestrogens do not prove normal ovarian function [9].
Measurement of Anti-Mullerian hormone and inhibin B
has been used to estimate remaining functional follicles.
According to ACOG (American College of Obstetricians and2 International Journal of Endocrinology
Table 1: Common and less common causes of POI.
Most common
investigating causes
of POI
Less common investigating causes of POI
Chromosomal
abnormalities
(gonadal dysgenesis
with or without
Turner syndrome)
Part of a multiple endocrinopathy
(i) hypoparathyroidism,
(ii) hypoadrenalism,
(iii) & mucocutaneous candidiasis
Premutation of
X-chromosome
(FMR1 gene)
Fragile X
syndrome
Autoimmune diseases such as
(i) autoimmune lymphocytic oophoritis,
(ii) dry-eye syndrome,
(iii) myasthenia gravis,
(iv) rheumatoid arthritis,
(v) systemic lupus erythematosus
Damage from
chemotherapy or
radiation therapy
Viral infections
Galactosemia
Surgical
oophorectomy
(surgical
extirpation)
Sarcoidosis
Gynecologists) the measurements of all the above are not
necessary for the diagnosis of POI [10].
Therapeutic goals of POI are emotional health, hormone
replacement therapy, maintenance of bone health, family
planning, and concern about associated disorders [4]. In
the event of coexistence of other endocrinologic issues,
abnormalities of karyotype or iatrogenic causes of POI, there
are several additional diagnostic procedures which must take
place, but they are beyond the scope of this paper.
2. Emotional Health
An important problem in treating these patients is that it
is diﬃcult to announce the medical situation to both the
teenagegirlandherparents.Themostcommonwordsyoung
patientsusetodescribehowtheyfeelafterreceivingthediag-
nosis are “shocked,” “confused,” and “devastated” [11].The
family feel themselves confronted by an immense problem
thatwillaﬀecttheirdaughter’s capacityforfertilizationwhile
also creating in them a feeling of “stigmatization” as well as
an acute sense of anxiety and insecurity [12].
When parents have fully understood the problem of
their teenage daughter, they can help her emotionally and
further provide her with support at diﬀerent times when the
teenageexperiencesemotionalswings.Parentsmustbeaware
that talking about POI with their daughter is an ongoing
process. Responses should be short and clear. Dialogue must
always be encouraged, and emotional feedback has to be
obtained periodically. Should the patient’s questions seem
irrelevant, parents need to understand what the hidden
message is. The patient’s outlook should be encouraged to
be positive, and her emotional state must be externalized.
Parents must help their daughter develop a sense of herself
and her purpose beyond biological motherhood. Since the
patient may become secretive and withdrawn, both the adult
adolescent patient and her parents need to seek out resources
for support. Patients’ parents should share their faith or
sources of hope and understanding with the child [13]. All
the above-mentioned procedures are long-lasting and have
to form the basis for a peaceful environment in which such
teenagers will grow up in.
3. Hormone Replacement Therapy (HRT)
Contrary to the case of menopausal women, teenagers need
to treat POI via long-term therapy, which not infrequently
may be necessary even before puberty. The combined
hormone therapy (oestrogen + progestin) should not be
administered before the completion of puberty (full devel-
opmentofsecondarysexualcharacteristics).Previouslythere
were no guidelines on dosage and styles of hormones.
However, recently the ACOG published a Committee Opin-
ion (Number 502) on Adolescent Health Care [10]. Sug-
gested doses and available routes in the prepubertal patient
are 25-microgram estradiol-17β transdermal patch (or 0.3
milligram conjugated estrogen orally or 0.2–0.5 milligram
micronized estradiol orally) and 2.5–5 milligrams/day oral
medroxyprogesterone acetate for 12–14 days every 30–60
days (or 100 milligrams/day oral micronized progesterone
for 12–14 days every 30–60 days).
Inthepostpubertalpatienttreatmentoptionscaninclude
combined hormone contraception or hormone replace-
ment. Suggested doses and available routes in this group
are 100-microgram estradiol-17β transdermal patch (or
0.625–1.25 milligrams/day oral conjugated estrogen) and
2 milligrams/day oral micronized progesterone with 10
milligrams oral medroxyprogesterone acetate daily for 12–
14 days every 30–60 days (or 200 milligrams oral micronized
progesterone daily for12–14 days every 30–60 days).
The dosage and route of administration of HRT is
extremely complex because of the chronicity (many years
of treatment) and because during that period of time many
changes take place at both the physical and psychological
level. There are rare cases where the estrogen needs are
greater in younger women than in menopausal women
because the ﬁrst category is required to achieve peak bone
mass, while the latter simply seeks maintenance of bone
health [7]. The HRT for the period before completion
of secondary sexual characteristics should be the smallest
possible (estrogen alone) in order to achieve maximum
heightincrease.Progestogencompoundmustbeaddedwhen
breakthrough bleeding occurs, in order to induce regular
withdrawal bleeding.
In virtually all cases treatment should be individual-
ized to the patient. It must be borne in mind that oral
administration of any estrogen exposes the liver to higher
concentrations than any other tissue. In contrast, a trans-
dermal patch provides estrogen as 17β-estradiol allowing
easy absorption, rapid metabolism, and low bioavailability.
Several studies have been conducted comparing use of
oral versus transdermal estrogens. Use of oral estrogens
leads to suppression of insulin-like growth factor I (IGF-
I) concentration, while transdermal estrogen did not have
an e g a t i v ee ﬀect on IGF-I [14]. In case-control studiesInternational Journal of Endocrinology 3
of postmenopausal women, transdermal estradiol has been
associated with a lower risk of venous thromboembolism
than has oral estrogen [15].
Despitethefactthattheﬁnaldecisionforrouteoftherapy
remains between any individual patient and her clinician,
based on current data, transdermal HRT should be the ﬁrst
choice for adolescent patients [16]. On the other hand, there
are several regions around the world, such as the Mediter-
ranean countries, where the warm and humid climate does
not allow the use of patches. To date, however, few studies
haveactuallyexaminedwhetherHRTadministrationreduces
the long-term risks of POF and no evidence-basedguidelines
for management of POF exist [17]. Despite the fact that
HRT is still a controversial topic as regards menopausal
women, there is no doubt among physicians that all women
with POI must replace their missing steroid hormones (both
estrogens and progesterone) for the time period until they
reach the usual age of menopause [18]. All patients with
POI who take HRT must be aware that they have a 5–
10% possibility of conceiving [19] and for this reason they
must use barrier contraceptive methods such as a condom
or intrauterine devices. The HRT should be discontinued in
the event of a positive pregnancy test and the woman must
be advised by a fetal specialist as concerns her possible new
“needs” of estrogen and progesterone, this time for the safer
maintenance of the starting pregnancy. Although combined
oral contraceptives (COCs) appear to be an acceptable
method for adolescents’ HRT, they provide more steroid
hormone than is needed for physiologic replacement and
are therefore not recommended as ﬁrst-line management
[4]. Alternative methods for HRT, such as percutaneous
estradiol gel and transvaginal progesterone gel, have been
introduced over the last few years and seem to be well
tolerated, reducing the incidence of the psychologic side
eﬀects (emotional lability, sleep disorders, depression) of
estrogen single therapy [20].
4. FamilyPlanningand SexualFunction
In cases of POI, couples typically have the options of
adoption or egg donation. As mentioned above, women
with POI may experience sporadic resumption of ovarian
function and spontaneous pregnancies can occur in 5–10%
of those with idiopathic POI [19, 21]. Currently, there are no
known markers that are associated with an increased rate of
remission and there are no therapies that have been shown
to restore ovarian function and fertility. Evidence suggests
that pregnancies might occur if women with POI managed
to suppress their high FSH concentrations, either with
ethinyloestradiol or with gonadotrophin-releasing hormone
analogues, and then followed ovulation induction protocols
using low-dose gonadotrophins [22].
Recent results of cryopreservation techniques of ovarian
tissue have raised hopes of fertility preservation in women
w h oa r ed u et or e c e i v ec h e m o t h e r a p yf o rc a n c e rt r e a t m e n t .
Analternativetocryopreservationofovariantissueisovarian
stimulation, provided that cancer treatment can be delayed
[23].Oocytesorembryoscanbecryopreservedafterstimula-
tion. Although there may be future developments in fertility
treatment, such as in vivo maturation of oocytes from
stem cells or primordial follicles, in vitro fertilization using
donor oocytes remains the mainstay of treatment for POI
women who wish to become pregnant. However, according
to several authors, these pregnancies are at increased risk
for ﬁrst trimester hemorrhage, gestational hypertension,
and/or preeclampsia, the delivery of small for gestational
age (SGA) neonates, and postpartum hemorrhage, although
these ﬁndings are controversial [24].
Since patients with POI have estrogen deﬁciency, it is
expected that there will be a degree of vaginal dryness. This
leadstoreducedarousal,lessfrequentsexualencounters,and
increased pain [25]. The above-mentioned factors diminish
thesenseofsexualwell-beingofyoungwomenwithPOIand,
in the case of adult patients who are embarking upon their
ﬁrst sexual experiences, can lead to complex psychosexual
impairment [26]. Adequate dosage of estrogen replacement
and occasionally androgen replacement, along with sexual
counseling, may be helpful in the management of sexual
dysfunction.
5. MaintainingBone Health
Estrogens have important anticatabolic and anabolic eﬀects
on bone remodeling. Consequently, estrogen deﬁciency
among patients with POI results in an imbalance between
osteoclast and osteoblast activity and a progressive loss of
bone mineral density (BMD). Popat et al. reported that
women with POI have lower bone density compared to
regularly menstruating women [27] .T h es a m er e s e a r c ht e a m
concluded that delay in diagnosis of POI contributes to
reduced bone density by delaying proper therapy. There are
no reports that suggest increased likelihood of fracture in
patients with primary ovarian insuﬃciency.
Since HRT has not proven to be completely eﬀective in
prevention of osteoporosis, additional preventive measures
such as calcium and vitamin D intake and weight-bearing
exercises should be taken. Adult and young women with
POI should engage in a variety of exercises, such as walking,
jogging, and stair climbing, along with resistance exercises
since these not only aid bone acquisition but also contribute
to improvement of cardiovascular circulation. The North
American Menopause Society guidelines for perimenopausal
and postmenopausal women recommend an intake of
1200mg of elemental calcium and at least 800 to 1000IU of
vitamin D3 per day [28].
There is uncertainty (i.e., no clear purpose) as regards
the frequency of dual-energy X-ray absorptiometry (DEXA)
scanning in adolescents with estrogen deﬁciency. In a recent
Committee Opinion (no. 502), the American College of
Obstetricians and Gynecologists refers to the proposal made
by a number of experts for annual monitoring of bone
density during early to midpuberty in order to document
peak bone accrual, and then every 2 years through late
adolescence. By contrast, other experts claimed that there
is no need for an annual DEXA scan, as the implications
of a low bone mineral density result in this population are
unclear, given the low risk of fracture and the potential for
long-term treatment of osteopenia or low bone mass. Up4 International Journal of Endocrinology
to now, use of bisphosphonates is not recommended in the
young population because of uncertain adverse eﬀects and
safety proﬁles, especially in cases of spontaneous pregnancy.
Crofton et al. recently published a study stating that the
type and proﬁle of hormone replacement are critical and
c a nh a v ec o n s i d e r a b l ee ﬀects on the bone health of women
with POI [29]. The author concluded that physiological sex
steroid replacement (transdermal estradiol, 100μgd a i l yf o r
week 1, 150μg for weeks 2–4; vaginal progesterone, 200mg
twice daily for weeks 3-4) has better eﬀects on bone mass
acquisition and turnover compared with standard HRT (oral
ethinyloestradiol 30μg and 1.5mg norethisterone daily for
weeks 1–3, week 4 “pill-free”). Further research in this area is
needed.
6.CardiovascularDisease
In 1978, the Framingham Study established that there is
an association between early menopause and increased
mortality from cardiovascular disease, with an estimated
1.8 relative risk of mortality from ischemic heart disease
in those with menopause under the age of 40 compared
with those with menopause at 49–55 [30, 31]. Kalantaridou
et al. published results demonstrating that young women
with POF have signiﬁcant vascular endothelial dysfunction.
Early onset of endothelial dysfunction associated with sex
steroid deﬁciency may contribute to the increased risk of car-
diovascular disease and mortality in these women. Hormone
therapy restores endothelial function within 6 months of
treatment [32]. Estrogen deﬁciency has also been correlated
with adverse eﬀects on lipid proﬁle (increased triglycerides,
reduced high-density lipoprotein cholesterol)[33], reduced
insulin sensitivity [34], and the metabolic syndrome [35], all
recognizedriskfactorsforthedevelopment ofcardiovascular
disease.
Adult and young women with POI should be counseled
astotobaccoavoidance,dailyexerciseforobesityprevention,
and an appropriate Mediterranean diet in order to achieve
optimal cardiovascular health. Blood pressure screening,
lipid proﬁle measurements, and cardiac imaging should be
performed and monitored by a specialist. HRT results in
an increased carotid pulsatility index [36], decreased blood
pressure, improved renal function, and lowered activation of
the renin-angiotensin system in this age group. In a com-
parisondrawnbetweenphysiologicalsexsteroidreplacement
regimens (transdermal estradiol and vaginal progesterone)
and standard (oral ethinylestradiol and norethisterone)
therapy for 12 months, the ﬁrst cited regimens showed better
results in the above-mentioned cardiovascular parameters
[37]. Because these therapies are long-lasting, the risk of
thromboembolic events such as pulmonary embolism or
deep vein thrombosis must be extensively and repeatedly
examined.
7. Conclusions
Every prepubertal girl, teenager or young woman, who
is diagnosed with primary ovarian insuﬃciency should
undergoextensivesearchbyagroupofspecialistsinareferral
center while, moreover, beneﬁting from special handling of
her case that will comprise aﬀection and understanding. The
followup, which of necessity will be long term, needs to
take place twice annually. The ﬁnal decision for mode of
therapy will be one taken mutually between the individual
patient and her clinician. Health care providers who counsel
these patients must possess comprehensive knowledge of
f e m a l er e p r o d u c t i v eb i o l o g ya sw e l la ss p e c i a ls e n s i t i v i t yt o
the emotional needs of these patients and their parents,
especially at the time of diagnosis. Further investigation
must also be carried out into the extent and severity of POI
complications and due consideration given to the taking of
all necessary precautionary measures.
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